


BioVie Email Formats
Biotechnology Research • Carson City, Nevada, United States • 21-50 Employees
BioVie Email Formats
BioVie uses 2 email formats. The most common is {first initial}{last name} (e.g., jdoe@bioviepharma.com), used 80% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}{last name} | jdoe@bioviepharma.com | 80% |
{first name}{last name} | johndoe@bioviepharma.com | 20% |
Key Contacts at BioVie
Amy Chappell
Member Board Of Directors
Paul Tanpiengco
Senior Director Of Operations
Michael Sherman
Member Board Of Directors
Company overview
| Headquarters | 680 W Nye Ln, Carson City, Nevada 89703, US |
| Phone number | +17758883162 |
| Website | |
| SIC | 283 |
| Keywords | Biotechnology, Clinical Trials, Dementia, Neuroscience, Clinical Research, Alzheimer'S, Scientific Research, Liver, Parkinson'S, Biotech, Liver Disease, Cirrhosis, Liver Cirrhosis, Cognitive Decline, Ascites, Neurodegenerative, Ne3107 |
| Founded | 2013 |
| Employees | 21-50 |
| Socials |
About BioVie
Focusing on Finding Solutions for Healthier Brain, Memory, and Movement. Our neurology strategy is centered at what we understand to be the nexus of biochemistry, cellular energetics, and neuroprotection, enabling us to explore the potential of our pipeline molecules to decrease inflammation, enhance glucose utilization, protect neurons, and facilitate energy transfer within the central nervous system, ultimately leading to improvements in memory and movement, and a healthier brain. Our lead Neuroscience molecule (NE3107) is currently being investigated in human clinical studies to assess its hypothesized impact on both Alzheimer’s and Parkinson’s. Exploring the possibilities of improved outcomes, fewer medical burdens, and more time at home. In our cirrhosis studies, we are working to learn if our exploratory technology can help individuals who have been diagnosed with cirrhosis-related ascites (fluid that builds up inside the abdomen) to be more comfortable, to require fewer or less frequent medical procedures to drain ascites fluid, and to see if the treatment can help people with ascites to live outside of the hospital for longer periods of time. BioVie is currently investigating BIV-201, a novel formulation of terlipressin, in human clinical trials. In BioVie’s studies of BIV-201, the exploratory medication is provided as a continuous infusion formulation delivered by a small, portable pump that the user can wear while engaging in typical tasks and activities at home. For more information about BioVie and our current studies, please visit our website https://bioviepharma.com/
Employees by Management Level
Total employees: 21-50
Seniority
Employees
Employees by Department
BioVie has 7 employees across 6 departments.
Departments
Number of employees
Funding Data
Explore BioVie's funding history, including investment rounds, total capital raised, and key backers.
BioVie Tech Stack
Discover the technologies and tools that power BioVie's digital infrastructure, from frameworks to analytics platforms.
Security
Security
Form builders
JavaScript frameworks
JavaScript libraries
JavaScript libraries
JavaScript libraries
JavaScript libraries
Maps
Page builders
JavaScript libraries
JavaScript libraries
Frequently asked questions
4.8
40,000 users



